CRISPR-Cas12a with an oAd Induces Precise and Cancer-Specific Genomic Reprogramming of EGFR and Efficient Tumor Regression.

Molecular Therapy : the Journal of the American Society of Gene Therapy
A-Rum YoonChae-Ok Yun

Abstract

CRISPR-Cas12a represents a class 2/type V CRISPR RNA-guided endonuclease, holding promise as a precise genome-editing tool in vitro and in vivo. For efficient delivery of the CRISPR-Cas system into cancer, oncolytic adenovirus (oAd) has been recognized as a promising alternative vehicle to conventional cancer therapy, owing to its cancer specificity; however, to our knowledge, it has not been used for genome editing. In this study, we show that CRISPR-Cas12a mediated by oAd disrupts the oncogenic signaling pathway with excellent cancer specificity. The intratumoral delivery of a single oAd co-expressing a Cas12a and a CRISPR RNA (crRNA) targeting the epidermal growth factor receptor (EGFR) gene (oAd/Cas12a/crEGFR) induces efficient and precise editing of the targeted EGFR gene in a cancer-specific manner, without detectable off-target nuclease activity. Importantly, oAd/Cas12a/crEGFR elicits a potent antitumor effect via robust induction of apoptosis and inhibition of tumor cell proliferation, ultimately leading to complete tumor regression in a subset of treated mice. Collectively, in this study we show precise genomic reprogramming via a single oAd vector-mediated CRISPR-Cas system and the feasibility of such system as an alt...Continue Reading

References

Aug 22, 2002·Cancer Gene Therapy·Jaesung KimChae-Ok Yun
Oct 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takayuki KosakaTetsuya Mitsudomi
Oct 19, 2006·Journal of the National Cancer Institute·Joo-Hang KimChae-Ok Yun
Jan 20, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ji Young YooChae-Ok Yun
Sep 1, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Peter GoldstrawUNKNOWN Participating Institutions
Dec 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·James BeanWilliam Pao
Feb 26, 2009·Journal of Carcinogenesis·Neelu Puri, Ravi Salgia
Apr 14, 2010·Molecular Cancer·J Rafael SierraSilvia Giordano
Jul 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistJoan H Schiller
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ahad A Sadiq, Ravi Salgia
Feb 15, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Helena A YuGregory J Riely
Jun 5, 2015·Nature Reviews. Cancer·Francisco J Sánchez-Rivera, Tyler Jacks
Mar 5, 2016·Oncoimmunology·Jonathan PolLorenzo Galluzzi
Apr 21, 2016·Nature·Ines FonfaraEmmanuelle Charpentier
Jun 9, 2016·Nature Biotechnology·Daesik KimJin-Soo Kim
Jun 28, 2016·Nature Biotechnology·Benjamin P KleinstiverJ Keith Joung
Aug 27, 2016·Briefings in Functional Genomics·Taeyoung Koo, Jin-Soo Kim
Dec 6, 2016·Nature Biotechnology·Bernd ZetscheFeng Zhang
Dec 20, 2016·Nature Methods·Hui K KimHyongbum Kim
Dec 23, 2016·Nature Reviews. Drug Discovery·Christof FellmannJacob E Corn
Jan 24, 2017·The Cancer Journal·Praveen K BommareddyHoward L Kaufman
Jan 31, 2017·Molecular Therapy. Nucleic Acids·Wei-Jing DaiXiao-Jie Lu
Feb 22, 2017·Nature Communications·Eunji KimJin-Soo Kim
Dec 1, 2017·Current Cancer Drug Targets·Min Liang
Jan 13, 2018·Genome Research·Wonjoo KimHyongbum Henry Kim
May 15, 2018·Frontiers in Immunology·Giulia MarelliYaohe Wang
Jan 9, 2019·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
May 30, 2019·Nature Communications·Naiara Martínez-VélezMarta M Alonso

❮ Previous
Next ❯

Citations

Mar 26, 2021·Molecular Cancer·Tina BriolayNicolas Boisgerault
Jun 2, 2021·Journal of Hematology & Oncology·Zhe ChengYongheng Chen
Sep 24, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Pin-Yi Wang, Timothy P Cripe

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons
Romesh P NalliahVeerasathpurush Allareddy
Neurosurgery
Mark GarrettCurtis A Dickman
© 2021 Meta ULC. All rights reserved